(NASDAQ: CMPX) Compass Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.88%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.63%.
Compass Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast CMPX's revenue for 2025 to be $1,700,874,725, with the lowest CMPX revenue forecast at $1,700,874,725, and the highest CMPX revenue forecast at $1,700,874,725. On average, 4 Wall Street analysts forecast CMPX's revenue for 2026 to be $2,146,420,934, with the lowest CMPX revenue forecast at $525,473,492, and the highest CMPX revenue forecast at $5,437,267,821.
In 2027, CMPX is forecast to generate $10,238,021,304 in revenue, with the lowest revenue forecast at $4,245,272,689 and the highest revenue forecast at $23,620,033,483.